Page last updated: 2024-11-10

7-chloro-N-(phenylmethyl)-4-quinolinamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4798096
CHEMBL ID528696
CHEBI ID116229
SCHEMBL ID13496121

Synonyms (22)

Synonym
smr000590020
MLS001175639
n-benzyl-7-chloro-quinolin-4-amine
CHEBI:116229
TCMDC-125506 ,
CHEMBL528696 ,
n-benzyl-7-chloroquinolin-4-amine
HMS2904J08
AKOS008922494
IMBPMAAMRHSTEU-UHFFFAOYSA-N
4-(n-benzyl)amino-7-chloroquinoline
SCHEMBL13496121
7-chloro-n-(phenylmethyl)-4-quinolinamine
Q27199022
Z31196920
4-benzylamino-7-chloroquinoline
865270-61-7
CCG-301676
bdbm50233286
CS-0231981
DTXSID301323947
EN300-126041

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" These results, supported by the in silico prediction of a good oral bioavailability and a suitable risk profile, propose the 4-amino-7-chloroquinoline scaffold as a potential template for designing trypanocidal prototypes."( In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
Escario, JA; Fonseca-Berzal, C; Gómez-Barrio, A; Kouznetsov, VV; Rojas Ruiz, FA, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoquinolineAny member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency10.31830.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency15.45940.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency17.78280.00527.809829.0929AID588855
hepatitis C virus polyproteinPotency9.95220.444510.437124.9988AID720575
IDH1Homo sapiens (human)Potency20.59620.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency8.19950.00419.984825.9290AID504444
pyruvate kinase PKM isoform aHomo sapiens (human)Potency15.84890.04017.459031.6228AID1631; AID1634
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
Glycoprotein hormones alpha chainHomo sapiens (human)Potency8.91254.46688.344810.0000AID624291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CruzipainTrypanosoma cruziIC50 (µMol)44.00000.00022.04508.0000AID1432587
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID1432590Inhibition of recombinant human cathepsin S at 100 uM using cbz-val-val-arg-7-amino-4-methylcoumarin as substrate measured for 15 mins by fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432592Inhibition of recombinant human cathepsin S at 100 uM using cbz-val-val-arg-7-amino-4-methylcoumarin as substrate preincubated for 5 mins followed by substrate addition measured for 15 mins by fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432600Selectivity index, ratio of CC50 for mouse L929 cells to IC50 for Trypanosoma cruzi Tulahuen trypomastigote forms infected in mouse L929 cells2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432585Inhibition of recombinant Trypanosoma cruzi cruzain at 100 uM using Z-phe-Arg-amidomethylcoumarin as substrate by fluorometric method relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432598Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigote forms infected in mouse L929 cells after 96 hrs by chlorophenol red-beta-D-galactopyranoside dye based assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID611732Inhibition of beta-hematine formation after 18 to 24 hrs by ferriprotoporphyrin 9 biomineralization inhibition test2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.
AID1070013Cytotoxicity against mouse NCTC-929 cells at 256 uM after 48 hrs by resazurin staining-based fluorescence assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID611730Antimalarial activity against erythrocytic stage chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs by fluorescence spectrophotometer2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1070014Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition after 72 hrs by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID611731Antimalarial activity against erythrocytic stage multidrug-resistant Plasmodium falciparum Dd2 after 48 hrs by fluorescence spectrophotometer2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.
AID1070015Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition at 256 uM after 72 hrs by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1070011Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for epimastigote stage of Trypanosoma cruzi CL Brener2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1432587Inhibition of recombinant Trypanosoma cruzi cruzain using Z-phe-Arg-amidomethylcoumarin as substrate by fluorometric method2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432594Inhibition of rat cathepsin B at 100 uM using cbz-phe-Arg-amidomethylcoumarin as substrate measured for 15 mins by fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432596Inhibition of rat cathepsin B at 100 uM using cbz-phe-Arg-amidomethylcoumarin as substrate preincubated for 5 mins followed by substrate addition measured for 15 mins by fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432599Cytotoxicity against mouse L929 cells after 96 hrs by alamar blue assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID611733Cytotoxicity against mouse macrophage J774 cells at 37 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.
AID1070012Cytotoxicity against mouse NCTC-929 cells after 48 hrs by resazurin staining-based fluorescence assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID611751Antimalarial activity against Plasmodium berghei str. ANKA infected in NMRI mouse at 10 mg/kg/day, ip for three days measured on day 4 by Giemsa staining2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.
AID1432586Inhibition of recombinant Trypanosoma brucei rhodesain at 100 uM using Z-phe-Arg-amidomethylcoumarin as substrate by fluorometric method relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID1432588Inhibition of recombinant Trypanosoma brucei rhodesain using Z-phe-Arg-amidomethylcoumarin as substrate by fluorometric method2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification.
AID611742Cytotoxicity against human HepG2 cells at 37 uM after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.
AID1764405Agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity at 10 uM incubated for 12 to 14 hrs by hybrid reporter gene assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745846Firefly Luciferase Counterscreen for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's8 (72.73)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.15 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]